ClearPoint Neuro (CLPT) to Release Quarterly Earnings on Wednesday

ClearPoint Neuro (NASDAQ:CLPT) will likely be posting its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:30 PM ET.

ClearPoint Neuro Stock Up 0.2%

CLPT opened at $13.58 on Wednesday. The company has a debt-to-equity ratio of 1.84, a current ratio of 6.37 and a quick ratio of 5.56. The firm has a market capitalization of $385.94 million, a P/E ratio of -16.17 and a beta of 1.01. The company’s 50-day moving average is $13.98 and its 200 day moving average is $15.50. ClearPoint Neuro has a fifty-two week low of $9.76 and a fifty-two week high of $30.10.

Insider Transactions at ClearPoint Neuro

In other news, CEO Joseph Burnett sold 2,943 shares of the stock in a transaction on Monday, January 26th. The shares were sold at an average price of $15.57, for a total value of $45,822.51. Following the completion of the sale, the chief executive officer directly owned 214,116 shares of the company’s stock, valued at $3,333,786.12. This represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 6.11% of the company’s stock.

Institutional Investors Weigh In On ClearPoint Neuro

A number of institutional investors have recently added to or reduced their stakes in CLPT. Vanguard Group Inc. grew its position in shares of ClearPoint Neuro by 1.5% during the third quarter. Vanguard Group Inc. now owns 1,497,637 shares of the company’s stock valued at $32,634,000 after purchasing an additional 22,517 shares in the last quarter. Millennium Management LLC grew its stake in ClearPoint Neuro by 156.3% in the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock worth $8,813,000 after acquiring an additional 452,043 shares in the last quarter. State Street Corp increased its holdings in ClearPoint Neuro by 30.1% during the 4th quarter. State Street Corp now owns 628,061 shares of the company’s stock worth $8,592,000 after purchasing an additional 145,411 shares during the period. FirstWave Capital Management LLC purchased a new position in shares of ClearPoint Neuro during the fourth quarter valued at $4,971,000. Finally, UBS Group AG raised its holdings in shares of ClearPoint Neuro by 132.1% in the 3rd quarter. UBS Group AG now owns 360,705 shares of the company’s stock valued at $7,860,000 after purchasing an additional 205,295 shares in the last quarter. 30.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CLPT has been the subject of several recent research reports. Wall Street Zen lowered ClearPoint Neuro from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $9.00.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.